The Canadian Diabetes Association guidelines: Putting the evidence first

CMAJ. Canadian Medical Association Journal

Volumn 174, Issue 3, 2006, Pages 333-334

  Howlett, Michael C ^a   Lillie, Donna ^a  

^a Canadian Diabetes Association   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN GLARGINE; ISOPHANE INSULIN;

CANADA; CLINICAL PRACTICE; DIABETES MELLITUS; DRUG FORMULARY; DRUG FORMULATION; EVIDENCE BASED PRACTICE; GLUCOSE BLOOD LEVEL; HEALTH CARE; HEALTH CARE PERSONNEL; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; MEDICAL SOCIETY; NOTE; PHYSICIAN; PRACTICE GUIDELINE;

EID: 32544432389     PISSN: 08203946     EISSN: 14882329     Source Type: Journal    
DOI: 10.1503/cmaj.051556     Document Type: Note

References (4)

1. Clinical practice guidelines and conflict of interest [editorial]. CMAJ 2005;173(II):1297, 1299. Available: www.cmaj.ca/cgi/content/full/173/11/1297 (accessed 2005 Dec 20).
2. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Canadian Diabetes Association 2003 clinical practice guidelines for the prevention and management of diabetes in Canada. Can J Diabetes 2003;27(Suppl 2):S1-152. Available: www.diabetes.ca/cpg2003 (accessed 2005 Dec 12).
3. International Diabetes Federation, Clinical Guidelines Task Force. Global guideline for type 2 diabetes. Available: www.idf.org/webdata/docs/IDF%20GGT2D. pdf (accessed 2005 Dec 12).
4. National Institute for Clinical Excellence. Final appraisal determination: long-acting insulin analogues for the treatment of diabetes - insulin glargine. Available: www.nice.org.uk/pdf/FAD_insulin_analogues.pdf (accessed 2005 Dec 12).